A prospective, observational study in a university hospital (UZ Leuven). Patients are included when they are treated with a potentional QT-prolonging drug: haloperidol for delirium, antibiotics (moxifloxacin, levofloxacin, azithromycin, clarithromycin, erythromycin, co-trimoxazole), antimycotics (ketoconazole, itraconazole, fluconazole, voriconazole), methadone, tacrolimus and oral oncolytics. An ECG is taken before the administration of the drug and 3-5 days after starting the drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation will be documented. Together with ECG2, an additional blood sample will be collected to measure the blood concentration of the drug.
Study Type
OBSERVATIONAL
Enrollment
178
UZ Leuven
Leuven, Belgium
change in QTc-interval (corrected for heart rate)
Time frame: before and 3-5 days after the start of a potentional QT-prolonging drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.